Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutrition in early life interacts with genetic risk to influence preadult behaviour in the Raine Study.

Communications medicine·2026
Same author

Impact of prematurity on lifelong cardiovascular health: structural and functional considerations.

NPJ cardiovascular health·2025
Same author

Cold storage of alarm substance reduces the behavioural stress response of zebrafish (Danio rerio).

Journal of fish biology·2025
Same author

The longitudinal effects of neonatal anthropometry on attention problems in males and females.

JCPP advances·2025
Same author

A shaking experience: My exposure to hypothermia.

Experimental physiology·2025
Same author

Neurosteroid replacement therapy using tiagabine and zuranolone restores cerebellar neurodevelopment and reduces hyperactive behaviour following preterm birth.

Journal of developmental origins of health and disease·2025

Related Experiment Video

Updated: Sep 24, 2025

Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders
05:00

Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders

Published on: November 11, 2022

2.5K

Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment.

Julia C Shaw1,2, Rebecca M Dyson3,4, Hannah K Palliser1,2

  • 1School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia.

Frontiers in Physiology
|May 6, 2022
PubMed
Summary

Ganaxolone, a neurosteroid-analogue, did not improve preterm brain development markers at term equivalence. High-dose ganaxolone impaired physical wellbeing, suggesting lower doses warrant further study for potential long-term benefits.

Keywords:
GABAglutamateneuronneurosteroidsoligodendrocytepreterm neonatal brain

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

350
Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

28.6K

Related Experiment Videos

Last Updated: Sep 24, 2025

Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders
05:00

Transplantation of Human Stem Cell-Derived GABAergic Neurons into the Early Postnatal Mouse Hippocampus to Mitigate Neurodevelopmental Disorders

Published on: November 11, 2022

2.5K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

350
Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

28.6K

Area of Science:

  • Neuroscience
  • Neonatal Development
  • Pharmacology

Background:

  • Preterm birth poses risks of neonatal brain injury with no current targeted therapies.
  • Previous studies indicated ganaxolone promotes white matter development in preterm male guinea pigs.
  • This study evaluated ganaxolone dosing for physical wellbeing and neurodevelopmental markers in preterm neonates.

Purpose of the Study:

  • To assess the impact of varying ganaxolone doses on physical wellbeing and neurodevelopment in preterm guinea pigs.
  • To identify safe and effective dosing strategies for ganaxolone in neonatal brain development.
  • To investigate ganaxolone's effects on hippocampal neurodevelopmental markers at term equivalence.

Main Methods:

  • Preterm guinea pigs (d62) and term-born controls (d69) were used.
  • Preterm neonates received daily ganaxolone (0.5, 1.0, or 2.5 mg/kg) or vehicle until term equivalence.
  • Physical parameters and hippocampal neurodevelopmental markers (immunohistochemistry, RT-PCR) were analyzed.

Main Results:

  • High-dose ganaxolone (2.5 mg/kg) significantly impaired physical parameters including weight gain and wellbeing.
  • Low and mid doses of ganaxolone showed minor impacts on early physical development.
  • Preterm hippocampus exhibited deficits in oligodendrocyte, neuronal growth, and neurotransmitter system markers, unaffected by ganaxolone doses.

Conclusions:

  • The highest dose of ganaxolone tested (2.5 mg/kg) negatively impacted physical health and wellbeing in preterm neonates.
  • Ganaxolone did not appear to affect neurodevelopmental markers at term equivalence at the doses used.
  • Further long-term studies with lower ganaxolone doses are recommended to evaluate functional outcomes for preterm-associated disorders.